Cochlear Ltd (ASX: COH) shares are pushing higher today.
Shares in the S&P/ASX 200 Index (ASX: XJO) hearing solutions company closed yesterday trading for $112.78. In early afternoon trade on Wednesday, shares are changing hands for $114.44 apiece, up 1.5%.
For some context, the ASX 200 is up 0.3% at this same time.
Unfortunately for longer-term stockholders, today's outperformance is not par for the course for Cochlear shares, which have plunged 61.5% over the last 12 months.
And while Cochlear did pay two partly-franked dividends over this time, the stock's 3.8% trailing dividend yield won't do much to ease those capital losses.
But with the ASX 200 stock down more than 60% in a year, is now the time for brave investors to pounce on a potential long-term bargain?
Image source: Getty Images
The bearish case for Cochlear shares
Peak Asset Management's Niv Dagan recently analysed the outlook for the ASX 200 hearings solutions company (courtesy of The Bull).
Commenting on the more recent selling pressure, he noted:
In April, the hearing implants maker materially reduced its fiscal year 2026 underlying net profit guidance to between $290 million and $330 million from between $435 million from $460 million in February.
The downgrade was a response to weaker than expected demand in developed markets amid Middle East uncertainty, lower margins and foreign exchange headwinds.
And Dagan expects Cochlear shares are likely to face ongoing headwinds over the medium term. Summarising his sell recommendation on the ASX 200 stock, he concluded:
Hospital capacity constraints amid softer consumer sentiment and reduced referral activity are weighing on implant volumes, while cost base restructuring is likely to impact earnings in the near term.
A more upbeat outlook for the ASX 200 stock
Bell Potter Securities' Christopher Watt also recently ran his slide rule over the beleaguered hearing solutions company.
And he sounded a more optimistic note on Cochlear's outlook.
"The long-term opportunity for this hearing implants maker remains compelling, supported by a large addressable market, strong brand position and an attractive product pipeline," Watt said.
But Watt isn't ready to pull the trigger just yet, issuing a hold recommendation on Cochlear shares.
According to Watt:
However, near term trading conditions have softened in response to weaker referral activity in the US, hospital capacity constraints in Europe and reimbursement changes in China. Until there's clearer evidence that volumes are stabilising, a more balanced stance is appropriate.
The long-term growth story and product pipeline remain intact.
Cochlear shares have enjoyed a strong rebound over the past month, up 17.8% since 25 May.
